Molecular residual disease (MRD), detected via circulating tumor DNA (ctDNA) after curative-intent surgery, identifies resectable solid tumor patients at high recurrence risk, thereby enabling enriched trials with larger effect sizes and smaller samples. Yet enrichment narrows the eligible population and thus challenge...
S. Kobayashi, T. Hashimoto, H. Bando et al.· Cancer Cell· 0 citations
Despite recent adoption of perioperative therapy for high-risk melanoma, its overall survival benefit remains unclear, highlighting the need for biomarkers to identify patients likely to benefit from treatment. Detection of circulating tumor DNA (ctDNA) after definitive treatment predicts recurrence, and emerging molec...
Yoshiaki Nakamura, K. Namikawa, D. Ogata et al.· Cancer Research Communicatio...· 0 citations
Results show that post-treatment circulating tumor RAS and BRAF MT dynamics may serve as useful prognostic indicators, particularly with regard to BRAF MT.
H. Osumi, E. Shinozaki, Yoshiaki Nakamura et al.· iScience· 0 citations
It is proposed that the next phase of precision oncology should integrate the cellular dimension of metastasis through systematic circulating tumor cell (CTC) profiling and highlights adherent-to-suspension transition (AST) as one representative, experimentally tractable plasticity program that enables tumor cells to s...
T. Hashimoto, T. Shibuki, T. Fujisawa et al.· International Journal of Cli...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
